John Johnson Sells 21,686 Shares of AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director John Johnson sold 21,686 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $29.98, for a total value of $650,146.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

John Johnson also recently made the following trade(s):

• On Monday, December 8th, John Johnson sold 23,693 shares of AxoGen stock. The shares were sold at an average price of $31.24, for a total transaction of $740,169.32.

AxoGen Trading Down 2.0%

Shares of NASDAQ:AXGN traded down $0.60 during trading on Wednesday, reaching $30.01. The stock had a trading volume of 679,926 shares, compared to its average volume of 854,756. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.64 and a current ratio of 4.09. The firm’s fifty day moving average is $22.57 and its 200 day moving average is $16.58. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -600.20 and a beta of 1.06. AxoGen, Inc. has a 52 week low of $9.22 and a 52 week high of $34.24.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.03. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%.The firm had revenue of $60.08 million during the quarter, compared to the consensus estimate of $56.90 million. As a group, equities analysts forecast that AxoGen, Inc. will post -0.29 EPS for the current fiscal year.

Institutional Trading of AxoGen

A number of institutional investors have recently bought and sold shares of the stock. Future Financial Wealth Managment LLC acquired a new stake in shares of AxoGen in the 3rd quarter worth $27,000. Aquatic Capital Management LLC increased its stake in shares of AxoGen by 287.8% in the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 1,269 shares during the period. State of Alaska Department of Revenue bought a new stake in AxoGen in the third quarter valued at approximately $43,000. Tower Research Capital LLC TRC raised its position in AxoGen by 189.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after buying an additional 3,327 shares during the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of AxoGen by 882.2% in the 2nd quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider’s stock valued at $68,000 after acquiring an additional 5,637 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on AXGN shares. Lake Street Capital raised their price objective on shares of AxoGen from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. JMP Securities set a $34.00 target price on AxoGen in a research note on Thursday, October 30th. Citizens Jmp increased their price target on shares of AxoGen from $26.00 to $34.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Raymond James Financial reissued an “outperform” rating and issued a $36.00 price target on shares of AxoGen in a report on Thursday, December 4th. Finally, Mizuho started coverage on AxoGen in a report on Monday, December 1st. They set an “outperform” rating and a $40.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and an average price target of $35.56.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.